Login
$ANRO
$27.12 +$0.00 (0.0%) After hours

$ANRO SEC Filings

Filed On Filing
16 Nov 2026 144
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

– PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 –

30 Oct 2026 SCHEDULE 13G
05 Oct 2026 Form 4: Smith Nicholas Conrad, PRESIDENT AND CFO

Received 55,000 shares by exercise or conversion ($128K)

01 Oct 2026 Form 4: Smith Nicholas Conrad, PRESIDENT AND CFO

Received 110,830 shares by exercise or conversion ($260K) · Sold 110,830 shares ($2.95M) · Received 24,056 shares by exercise or conversion ($56.5K) · 1 more

29 Sep 2026 144
27 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

As you know, you are currently employed at Alto Neuroscience, Inc. (the “Company”) as Chief Financial Officer and Chief Business Officer pursuant to the terms of an offer letter dated November 20, 2023, as amended by a letter agreement d...

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b dat...

27 Jul 2026 SCHEDULE 13G
20 Jul 2026 SCHEDULE 13G
14 Jul 2026 8-K: Entry into a Material Definitive Agreement

Alto Neuroscience, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall...

14 Jul 2026 424B5
13 Jul 2026 8-K: Results of Operations and Financial Condition; Other Events

The information disclosed under the heading “Cash, Cash Equivalents and Restricted Cash as of June 30, 2026” under Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference and shall not be deemed “filed” for purpo...

29 May 2026 Form 4: Miller Andrew Craig, Director

Granted 26,000 Stock Option (right to buy)

29 May 2026 Form 3: Miller Andrew Craig, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support